



Billing Code 4410-09-M

DEPARTMENT OF JUSTICE
DRUG ENFORCEMENT ADMINISTRATION
IMPORTER OF CONTROLLED SUBSTANCES
NOTICE OF APPLICATION
R & D SYSTEMS, INC.

Pursuant to Title 21 Code of Federal Regulations
1301.34 (a), this is notice that on May 4, 2012, R & D
Systems, Inc., 614 McKinley Place NE, Minneapolis,
Minnesota 55413, made application to the Drug Enforcement
Administration (DEA) for registration as an importer of the
following basic classes of controlled substances:

Drug	Schedule
1-Pentyl-3-(1-naphthoyl)indole (7118)	I
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3- hydroxycyclohexyl]-phenol (7297)	I
Marihuana (7360)	I
Tetrahydrocannabinols (7370)	I
4-Bromo-2,5-dimethoxyamphetamine (7391)	I
3,4-Methylenedioxymethamphetamine (7405)	I
Dimethyltryptamine (7435)	I

Drug	Schedule
Amphetamine (1100)	II
Methylphenidate (1724)	II
Phencyclidine (7471)	II
Cocaine (9041)	II
Oxycodone (9143)	II
Thebaine (9333)	II
Fentanyl (9801)	II

The company plans to import the listed controlled substances in dosage form to distribute to researchers.

In reference to drug codes 7360 and 7370, the company plans to import a synthetic cannabidiol and a synthetic Tetrahydrocannabinol. No other activity for this drug code is authorized for this registration.

The import of the above listed basic classes of controlled substances would be granted only for analytical testing and clinical trials. This authorization does not extend to the import of a finished FDA approved or non-approved dosage form for commercial distribution in the United States.

Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic

classes of controlled substances listed in schedules I or II, which fall under the authority of section 1002(a)(2)(B) of the Act 21 USC § 952 (a)(2)(B) may, in the circumstances set forth in 21 USC § 958(i), file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR § 1301.43 and in such form as prescribed by 21 CFR § 1316.47.

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than [INSERT DATE 30 DAYS FROM DATE OF PUBLICATION].

This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR § 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, 40 FR 43745-46, all applicants for registration to import a basic class of any controlled substances in schedules I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21

USC § 958(a); 21 USC § 823(a); and 21 CFR § 1301.34(b),
(c), (d), (e), and (f) are satisfied.

Joseph T. Rannazzisi
Deputy Assistant Administrator
Office of Diversion Control
Drug Enforcement Administration

DATED: July 31, 2012

[FR Doc. 2012-19193 Filed 08/06/2012 at 8:45 am; Publication Date: 08/07/2012]